Using mouse melanoma and breast cancer models as well as an experimental metastasis model, we have provided compelling preclinical evidence supporting the superior antitumor potency of the Flagrp170-based chaperone complex vaccine targeting gp100 or the Her2/neu antigen when compared to a chaperone vaccine similarly prepared with unmodified Grp170. This evidence concerns the gene HYOU1 and breast cancer.